Talzenna
FDA Grants New Indication for Talzenna with Enzalutamide for HRR Gene-mutated mCRPC
The FDA approved Talzenna with enzalutamide for homologous recombination repair gene-mutated metastatic ...
JUNE 28, 2023
Adding Talazoparib to Enzalutamide in mCRPC Improves Outcomes
In patients with metastatic, castration-resistant prostate cancer, adding the PARP inhibitor talazoparib (Talzenna, ...
MARCH 17, 2023
FDA Approves Talzenna for gBRCAm HER2-Negative Breast Cancer
The FDA approved Talzenna, a poly(adenosine diphosphate–ribose) polymerase inhibitor, for patients with ...
OCTOBER 16, 2018
Load more